<i>UGT1A1</i> Polymorphism for Irinotecan Dose Escalation in Patients with <i>BRAF</i>-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI

<div>Flowchart of patient selection.</div>

Journal of Oncology

fig1

Figure 1

Figure 1: <i>UGT1A1</i> Polymorphism for Irinotecan Dose Escalation in Patients with <i>BRAF</i>-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI 

Figure 1 | UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI 